Jing H Ma from 1531 Jonesboro Ct, San Jose, CA 95131, age 60, Phone: 408 441-8312

Lawyers & Attorneys

Jing Ma - Lawyer

view source

Specialties:

Commercial Transactions
Mergers and Acquisitions
Securities
Corporate Law
Arbitration
Litigation

ISLN:

918685122

Admitted:

2005

University:

Peking University, Beijing, China, B.A., 1996; Peking University, Beijing, China, B.A., 1996; Peking University, Beijing, China, M.A., 1999; Peking University, Beijing, China, M.A., 1999

Law School:

Boston University, J.D., 2004

Name / Title

Company / Classification

Phones & Addresses

Jing Ma
Director, President, Secretary, Treasurer

Bay Area Labs, Inc

34313 Gadwall Cmn, Fremont, CA 94555

Us Patents

System For Operating A Programmable Logic Device Having A Defective Region
view source
US Patent:

7228521, Jun 5, 2007
Filed:

Feb 1, 2005
Appl. No.:

11/048333
Inventors:

Jing Hua Ma - San Jose CA, US
Benhai Zhang - San Jose CA, US
Assignee:

XILINX Inc. - San Jose CA
International Classification:

G06F 17/50
H03K 19/00
US Classification:

716 17, 716 12, 716 14
Abstract:

A code is generated for a programmable logic device (“PLD”) having a plurality of regions including at least one defective region. The code indicates a defective region or regions of the PLD. A user enters the code before running placement and routing. A guide file associated with the code blocks out the defective region(s) of the PLD during placement and routing.

Methods For Improvement Of Lung Function Using Tgf-Beta Inhibitors
view source
US Patent:

20040146509, Jul 29, 2004
Filed:

Jul 23, 2003
Appl. No.:

10/626004
Inventors:

Zhihe Li - Foster City CA, US
David Liu - Palo Alto CA, US
Jing Ma - Cupertino CA, US
Andrew Protter - Palo Alto CA, US
George Schreiner - Los Altos CA, US
International Classification:

A61K039/395
US Classification:

424/144100
Abstract:

The invention concerns methods for improvement of lung function by administering non-peptide small molecule inhibitors of TGF- specifically binding to the type I TGF- receptor (TGF-R1). Preferably, the inhibitors are quinazoline derivatives.

Nitrobenzyl Derivatives Of Anti-Cancer Agents
view source
US Patent:

20210017120, Jan 21, 2021
Filed:

Sep 29, 2020
Appl. No.:

17/036588
Inventors:

- Taipei City, TW
Yeyu Cao - South San Francisco CA, US
Xiaohong Cai - South San Francisco CA, US
Hailong Jiao - South San Francisco CA, US
Jing Yuan Ma - South San Francisco CA, US
Mark Matteucci - South San Francisco CA, US
Assignee:

OBI PHARMA, INC. - Taipei City
International Classification:

C07C 217/58
C07D 405/12
C07F 9/6558
A61K 47/64
C07D 403/06
A61K 47/55
A61P 35/00
C07D 239/94
C07D 487/04
C07D 471/04
C07C 213/02
C07D 491/22
C07H 19/06
Abstract:

Provided herein are compounds of formula I:wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

Dna Alkylating Agents
view source
US Patent:

20190225633, Jul 25, 2019
Filed:

Mar 28, 2019
Appl. No.:

16/368753
Inventors:

- Taipei City, TW
Yeyu Cao - South San Francisco CA, US
Xiaohong Cai - South San Francisco CA, US
Hailong Jiao - South San Francisco CA, US
Jing Yuan Ma - South San Francisco CA, US
Mark Matteucci - South San Francisco CA, US
Assignee:

OBI PHARMA, INC. - Taipei City
International Classification:

C07F 9/24
G01N 33/574
A61K 31/396
Abstract:

Provided herein are compounds of formula I:wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

(R)- And (S)-1-(3-(3-N,N-Dimethylaminocarbonyl)Phenoxyl-4-Nitrophenyl)-1-Ethyl-N,N'-Bis (Ethylene)Phosphoramidate, Compositions And Methods For Their Use And Preparation
view source
US Patent:

20180258116, Sep 13, 2018
Filed:

Nov 15, 2016
Appl. No.:

15/752854
Inventors:

- Taipei City, TW
Yeyu Cao - South San Francisco CA, US
Xiaohong Cai - South San Francisco CA, US
Hailong Jiao - South San Francisco CA, US
Jing Yuan Ma - South San Francisco CA, US
Mark Matteucci - South San Francisco CA, US
Assignee:

OBI Pharma, Inc. - Taipei City
International Classification:

C07F 9/564
A61P 35/00
Abstract:

Provided herein are optically active compounds of the formulae (ii); and (III) and pharmaceutical compositions thereof. Also provided herein are processes of making these compounds and resolving the racemic mixture or the enrichment of same with in one of its enantiomers to provide (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N′-bis(ethylene)phosphoramidate, and methods of treating cancer comprising administering such compounds.

Aziridine Containing Dna Alkylating Agents
view source
US Patent:

20180169064, Jun 21, 2018
Filed:

Jun 23, 2016
Appl. No.:

15/736285
Inventors:

- South San Francisco CA, US
Xiaohong Cai - South San Francisco CA, US
Yeyu Cao - South San Francisco CA, US
Hailong Jiao - South San Francisco CA, US
Jing Yuan Ma - South San Francisco CA, US
Jian-Xin Duan - South San Francisco CA, US
International Classification:

A61K 31/396
A61K 31/4168
A61K 31/4178
A61K 31/665
A61K 31/675
A61P 35/00
Abstract:

Provided herein are compounds of formula (I)-(VI), wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

Nitrobenzyl Derivatives Of Anti-Cancer Agents
view source
US Patent:

20180086693, Mar 29, 2018
Filed:

Apr 1, 2016
Appl. No.:

15/563481
Inventors:

- Taipei City, TW
Yeyu Cao - South San Francisco CA, US
Xiaohong Cai - South San Francisco CA, US
Hailong Jiao - South San Francisco CA, US
Jing Yuan Ma - South San Francisco CA, US
Mark Matteucci - South San Francisco CA, US
Assignee:

OBI PHARMA, INC. - Taipei City
International Classification:

C07C 217/58
C07D 491/22
C07D 405/12
C07C 213/02
C07H 19/06
Abstract:

Provided herein are compounds of formula I, wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

Dna Alkylating Agents
view source
US Patent:

20180044360, Feb 15, 2018
Filed:

Mar 9, 2016
Appl. No.:

15/557053
Inventors:

- Taipei City, TW
Yeyu Cao - South San Francisco CA, US
Xiaohong Cai - South San Francisco CA, US
Hailong Jiao - South San Francisco CA, US
Jing Yuan Ma - South San Francisco CA, US
Mark Matteucci - South San Francisco CA, US
Assignee:

OBI PHARMA, INC. - Taipei City
International Classification:

C07F 9/24
G01N 33/574
Abstract:

Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.